Company Analysis
Sign in

Kura Oncology, Inc. (KURA)

Nasdaq: KURA · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2008
Full chart Alerts Compare
Grade5.9
◀ Past 7.3● Present 4.7▶ Future 6.2
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

33 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Kura Oncology, Inc.’s names, not what it holds today.

Patents granted
33
32 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 8 in 2023
Applications published
57
10 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Organic fine chemistry7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Kura Oncology, Inc. its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in CA)
0 granted
53 published
Kura Oncology, Inc. its own name
US, as the owner printed on each patent
33 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 11, 202512,466,835Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the sameOrganic fine chemistryKura Oncology, Inc.
Sep 9, 202512,410,184Crystalline forms of a menin inhibitorOrganic fine chemistryKura Oncology, Inc.
Jun 25, 202412,018,011Macrocyclic compounds and compositions, and methods of preparing and using the sameOrganic fine chemistryKura Oncology, Inc.
Apr 2, 202411,944,627Methods for treating hematological malignancies and Ewing's sarcomaPharmaceuticalsKura Oncology, Inc.
Oct 10, 2023RE49,687Thienopyrimidine and thienopyridine compounds and methods of use thereofKura Oncology, Inc.
Jun 13, 202311,673,898Substituted inhibitors of menin-MLL and methods of useOrganic fine chemistryKura Oncology, Inc.
Jun 13, 202311,672,774Methods of treating squamous cell carcinomas with farnesyltransferase inhibitorsPharmaceuticalsKura Oncology, Inc.
May 16, 202311,649,251Substituted inhibitors of menin-MLL and methods of useOrganic fine chemistryKura Oncology, Inc.
Jan 17, 202311,555,041Bridged bicyclic inhibitors of menin-MLL and methods of usePharmaceuticalsKura Oncology, Inc.
Jan 3, 202311,542,248Methods and compositions for inhibiting the interaction of menin with MLL proteinsOrganic fine chemistryKura Oncology, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0361242CRYSTALLINE FORMS OF A MENIN INHIBITOROrganic fine chemistryKura Oncology, Inc.
Nov 6, 20252025/0340566BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USEPharmaceuticalsKura Oncology, Inc.
Oct 16, 20252025/0320229SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USEPharmaceuticalsKura Oncology, Inc.
Oct 16, 20252025/0320225SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USEOrganic fine chemistryKura Oncology, Inc.
Oct 2, 20252025/0304589METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINSOrganic fine chemistryKura Oncology, Inc.
Aug 14, 20252025/0255869METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMAPharmaceuticalsKura Oncology, Inc.
Jun 12, 20252025/0186445TREATMENT OF CANCER WITH MENIN INHIBITORS AND IMMUNO-ONCOLOGY AGENTSPharmaceuticalsKura Oncology, Inc.
May 15, 20252025/0152591TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORSPharmaceuticalsKura Oncology, Inc.
Mar 27, 20252025/0101035CRYSTALLINE FORMS OF A MENIN INHIBITOROrganic fine chemistryKura Oncology, Inc. · patent 12,410,184 granted from it
Mar 27, 20252025/0099469PHARMACEUTICAL COMPOSITIONS COMPRISING A MENIN INHIBITORPharmaceuticalsKura Oncology, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Organic fine chemistry 5.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KURA · research, not advice